Therapeutic Potential of Bimatoprost for the Treatment of Eyebrow Hypotrichosis

The document from 2018 reviews the use of bimatoprost, an FDA-approved treatment for eyelash hypotrichosis, for its potential to treat eyebrow hypotrichosis, a condition of reduced eyebrow hair. It cites several studies, including one by Smith et al. involving 278 patients and another by Glaser et al. with 368 subjects, which demonstrate the effectiveness and safety of bimatoprost in improving eyelash length, darkness, and fullness. The document also references studies by Elias et al., Schweiger et al., Suwanchatchai et al., Beer et al., Vergilis-Kalner, and Carruthers et al., which support the positive effects of bimatoprost on eyebrow growth. Side effects are minimal and include conjunctival hyperemia, pruritus, and skin hyperpigmentation, but no serious issues like iris hyperpigmentation or periorbital fat atrophy were reported. The document concludes that bimatoprost is a safe, effective, and well-tolerated option for enhancing eyebrow hair, although it does not provide specific results or conclusions from the studies mentioned.